Growth Metrics

Neogenomics (NEO) Cash & Current Investments (2016 - 2026)

Neogenomics filings provide 17 years of Cash & Current Investments readings, the most recent being $146.1 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 59.19% to $146.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $146.1 million, a 59.19% decrease, with the full-year FY2025 number at $159.6 million, down 58.74% from a year prior.
  • Cash & Current Investments hit $146.1 million in Q1 2026 for Neogenomics, down from $159.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $481.4 million in Q1 2022 to a low of $146.1 million in Q1 2026.
  • Median Cash & Current Investments over the past 5 years was $387.9 million (2024), compared with a mean of $353.7 million.
  • Biggest five-year swings in Cash & Current Investments: dropped 3.59% in 2024 and later crashed 59.19% in 2026.
  • Neogenomics' Cash & Current Investments stood at $438.0 million in 2022, then dropped by 5.2% to $415.2 million in 2023, then fell by 6.83% to $386.8 million in 2024, then crashed by 58.74% to $159.6 million in 2025, then dropped by 8.44% to $146.1 million in 2026.
  • The last three reported values for Cash & Current Investments were $146.1 million (Q1 2026), $159.6 million (Q4 2025), and $164.1 million (Q3 2025) per Business Quant data.